CD8 T lymphocytes from immunologically stable HIV-1-infected secrete a soluble factor — termed CAF —, which suppresses HIV-1 replication, but the exact identity of CAF has been unclear. In September ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

A chemical modification in the HIV-1 RNA genome whose function has been a matter of scientific debate is now confirmed to be key to the virus's ability to survive and thrive after infecting host cells ...

There is currently no cure for HIV, but medications can help people with the disease manage their symptoms. HIV can still develop into AIDS years after infection, however, even with disease management ...

It was previously demonstrated that the HIV-1 integrase (IN)-interacting host factor INI1/SMARCB1 binds to HIV-1 IN through its Rpt1 domain of INI1 (INI1-Rpt1) and plays a key role in assembly and ...

In a recent study published in the journal PLOS Biology, researchers in France investigated the cellular function and antiviral role of human SAMD9L and its paralog SAMD9 (short for sterile alpha ...

In an important discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human immunodeficiency ...

HIV-1 infection, in combination with other antiretrovirals, in treatment-experienced adults with evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals. Raltegravir ...

In a randomized trial, ART intensification by doubling the dolutegravir dosage in people with HIV stably suppressed on ...